Compare NICE Ltd (NICE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Zoetis Inc — how do they compare? NICE Ltd trades at $94.34 (market cap $5.91B), while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 5.4× NICE Ltd's market cap, and Zoetis Inc pays a 2.78% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| NICE | ZTS | |
|---|---|---|
Market Cap | $5.91B | $31.95B |
Sector | Technology | Health |
52-Week High | $170.37 | $156.76 |
52-Week Low | $83.15 | $71.91 |
Enterprise Value | $5.69B | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE trades at $101.34, up 1.19% today, with a bullish technical signal and strong support near $99. The stock shows solid fundamentals with a P/E of 12.02, net income margin of 17.57%, and consistent earnings beats in recent quarters. Recent news highlights enterprise AI deployments with Banco do Brasil and Sopra Steria, reinforcing growth in customer engagement solutions.
The outlook remains positive with a consensus price target of $123.33, representing 22% upside potential. Risks include competitive pressures in AI software and potential margin compression, but analyst sentiment is strongly bullish with no sell ratings. Institutional interest is supported by robust cash flow generation and strategic AI expansions.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
